OncoMatch/Clinical Trials/NCT04740424
FS222 First in Human Study in Patients With Advanced Malignancies
Is NCT04740424 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies FS222 for advanced cancer.
Treatment: FS222 — This study will be conducted in adult participants diagnosed with advanced tumours to characterize the safety, tolerability, pharmacokinetics (PK), and activity of FS222. This is a Phase 1, multi-center, open label, multiple-dose, first in human study, designed to systematically assess safety and tolerability, and to identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) for FS222 in participants with advanced tumours. Pharmacokinetics, pharmacodynamics, immunogenicity, and response will also be assessed.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: CD137 agonist monoclonal antibody or other experimental agonists
Prior treatment with CD137 agonist mAb or other experimental agonists
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04740424 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior CD137 agonist monoclonal antibody or other experimental agonists disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify